Advertisement

Psychopharmacology

, Volume 182, Issue 1, pp 104–115 | Cite as

Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats

  • Han-Ting ZhangEmail author
  • Ying Huang
  • Kathleen Mishler
  • Sandra C. Roerig
  • James M. O'Donnell
Original Innvestigation

Abstract

Rationale

Type 4 phosphodiesterase (PDE4) is critical for hydrolysis of cAMP formed by stimulation of beta adrenergic receptors. However, it is not known if PDE4 is associated with beta adrenergic receptors in the mediation of antidepressant-like effects.

Objective

The aim of the study is to determine the relationship between PDE4 and beta adrenergic receptor-mediated cAMP signaling in mediating antidepressant-like effects.

Methods

The effects of the PDE4 inhibitor rolipram, alone or combined with dobutamine or clenbuterol, selective beta-1 and beta-2 adrenergic agonists, respectively, on behavior were examined in rats under a differential reinforcement of low rate (DRL) schedule and rats trained to discriminate rolipram from vehicle. Their effects on cAMP in primary cultures of rat cerebral cortical neurons also were determined.

Results

Rolipram (0.01–0.3 mg/kg), dobutamine (1–30 mg/kg), and clenbuterol (0.03–0.3 mg/kg) dose-dependently produced antidepressant-like effects on DRL behavior, decreasing response rate and increasing reinforcement rate. The effects of beta adrenergic agonists were potentiated by rolipram. Isobolographic analysis revealed that rolipram enhanced the antidepressant-like effect of dobutamine additively and that of clenbuterol synergistically. Consistently, a combination of ineffective doses of rolipram (0.03 mg/kg) and dobutamine (3 mg/kg) or clenbuterol (0.03 mg/kg) completely substituted for the rolipram discrimination stimulus. Further, incubation with an ineffective concentration of clenbuterol, but not dobutamine, in the presence of a subeffective concentration of rolipram, significantly increased cAMP in cultured cortical neurons.

Conclusions

PDE4 plays an important role in regulating cAMP signaling by either beta-1 or beta-2 adrenergic receptors that mediate antidepressant-like actions; beta-2 adrenergic receptor-mediated cAMP signaling appears more responsive than beta-1 cAMP signaling to PDE4 inhibition.

Keywords

Beta adrenergic receptors Phosphodiesterase (PDE4) Cyclic AMP Antidepressant Drug discrimination Isobole Differential reinforcement of low rate (DRL) Rolipram Dobutamine Clenbuterol 

Notes

Acknowledgements

This study was supported by research grants and an Independent Scientist Award from the National Institute of Mental Health. The authors thank Mr. Ajay K Venkatesan and Mr. Gerald K. McKinnie for their assistance with the experiments.

References

  1. Baker SP, Sumners C, Pitha J, Raizada MK (1986) Characteristics of the beta adrenoreceptor from neuronal and glial cells in primary cultures of rat brain. J Neurochem 47:1318–1326PubMedCrossRefGoogle Scholar
  2. Crissman AM, Makhay MM, O'Donnell JM (2001) Discriminative stimulus effects of centrally administered isoproterenol in rats: mediation by beta-1 adrenergic receptors. Psychopharmacology (Berl) 154:70–75CrossRefGoogle Scholar
  3. Crissman AM, O'Donnell JM (2002) Effects of antidepressants in rats trained to discriminate centrally administered isoproterenol. J Pharmacol Exp Ther 302:606–611CrossRefPubMedGoogle Scholar
  4. Finnegan KT, Terwilliger MM, Berger PA, Hollister LE, Csernansky JG (1987) A comparison of the neurochemical and behavioral effects of clenbuterol and desipramine. Eur J Pharmacol 134:131–136CrossRefPubMedGoogle Scholar
  5. Fujita H, Tanaka J, Maeda N, Sakanaka M (1998) Adrenergic agonists suppress the proliferation of microglia through beta 2-adrenergic receptor. Neurosci Lett 242:37–40CrossRefPubMedGoogle Scholar
  6. Green SA, Holt BD, Liggett SB (1992) Beta 1- and beta 2-adrenergic receptors display subtype-selective coupling to Gs. Mol Pharmacol 41:889–893PubMedGoogle Scholar
  7. Guerrero SW, Zhong H, Minneman KP (1995) Selective desensitization of beta 1- and beta 2-adrenergic receptors in C6 glioma cells. Effects on catecholamine responsiveness. Receptor 5:185–195PubMedGoogle Scholar
  8. Gurguis GN, Vo SP, Griffith JM, Rush AJ (1999) Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol 386:135–144CrossRefPubMedGoogle Scholar
  9. Hichami A, Boichot E, Germain N, Legrand A, Moodley I, Lagente V (1995) Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Eur J Pharmacol 291:91–97CrossRefPubMedGoogle Scholar
  10. Kimmel HL, Tallarida RJ, Holtzman SG (1997) Synergism between buprenorphine and cocaine on the rotational behavior of the nigrally-lesioned rat. Psychopharmacology (Berl) 133:372–377CrossRefGoogle Scholar
  11. Lacoste A, Malham SK, Cueff A, Poulet SA (2001) Noradrenaline modulates oyster hemocyte phagocytosis via a beta-adrenergic receptor-cAMP signaling pathway. Gen Comp Endocrinol 122:252–259CrossRefPubMedGoogle Scholar
  12. Lecrubier Y, Puech AJ, Frances H, Jouvent R, Widlocher D, Simon P (1981) Beta-adrenergic stimulation and antidepressant activity. Acta Psychiatr Scand Suppl 290:173–178PubMedCrossRefGoogle Scholar
  13. Laemont KD, Schaefer CJ, Juneau PL, Schrier DJ (1999) Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats. Int J Immunopharmacol 21:711–725CrossRefPubMedGoogle Scholar
  14. Levitzki A (1988) From epinephrine to cyclic AMP. Science 241:800–806PubMedCrossRefGoogle Scholar
  15. Levy FO, Zhu X, Kaumann AJ, Birnbaumer L (1993) Efficacy of beta 1-adrenergic receptors is lower than that of beta 2-adrenergic receptors. Proc Natl Acad Sci U S A 90:10798–10802PubMedCrossRefGoogle Scholar
  16. Makhay MM, Houslay MD, O'Donnell JM (2001) Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats. Psychopharmacology (Berl) 158:297–304CrossRefGoogle Scholar
  17. Morin D, Sapena R, Tillement JP, Urien S (2000) Evidence for different interactions between beta(1)- and beta(2)-adrenoceptor subtypes with adenylyl cyclase in the rat brain: a concentration-response study using forskolin. Pharmacol Res 41:435–443CrossRefPubMedGoogle Scholar
  18. Murugaiah KD, O'Donnell JM (1995a) Facilitation of noradrenaline release from rat brain slices by β-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 351:483–490CrossRefGoogle Scholar
  19. Murugaiah KD, O'Donnell JM (1995b) Facilitation of norepinephrine release from cerebral cortex is mediated by beta2-adrenergic receptors. Life Sci 57:PL327–PL332CrossRefPubMedGoogle Scholar
  20. O'Donnell JM (1988) Psychopharmacological consequences of activation of beta adrenergic receptors by SOM-1122. J Pharmacol Exp Ther 246:38–46PubMedGoogle Scholar
  21. O'Donnell JM (1990) Behavioral effects of beta adrenergic agonists and antidepressant drugs after down-regulation of beta-2 adrenergic receptors by clenbuterol. J Pharmacol Exp Ther 254:147–157PubMedGoogle Scholar
  22. O'Donnell JM (1993) Effects of the beta-2 adrenergic agonist zinterol on DRL behavior and locomotor activity. Psychopharmacology (Berl) 113:89–94CrossRefGoogle Scholar
  23. O'Donnell JM, Frith S (1999) Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav 63:185–192CrossRefPubMedGoogle Scholar
  24. O'Donnell JM, Zhang HT (2004) Antidepressant effects of inhibitors of cyclic AMP phosphodiesterase (PDE4). Trends Pharmacol Sci (TIPS) 25:158–163CrossRefGoogle Scholar
  25. O'Donnell JM, Frith S, Wilkins J (1994) Involvement of beta-1 and beta-2 adrenergic receptors in the antidepressant-like effects of centrally administered isoproterenol. J Pharmacol Exp Ther 271:246–254PubMedGoogle Scholar
  26. O'Donnell JM, Marek GJ, Seiden LS (2005) Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev, in pressGoogle Scholar
  27. Ordway GA, O'Donnell JM, Frazer A (1987) Effects of clenbuterol on central beta-1 and beta-2 adrenergic receptors of the rat. J Pharmacol Exp Ther 241:187–195PubMedGoogle Scholar
  28. Ordway GA, Gambarana C, Frazer A (1988) Quantitative autoradiography of central beta adrenoceptor subtypes: comparison of the effects of chronic treatment with desipramine or centrally administered l-isoproterenol. J Pharmacol Exp Ther 247:379–389PubMedGoogle Scholar
  29. Paetsch PR, Greenshaw AJ (1993) Effects of chronic antidepressant treatment on beta-adrenoceptor subtype binding in the rat cerebral cortex and cerebellum. Mol Chem Neuropathol 20:21–31PubMedCrossRefGoogle Scholar
  30. Perez J, Tardito D, Mori S, Racagni G, Smeraldi E, Zanardi R (2000) Abnormalities of cAMP signaling in affective disorders: implication for pathophysiology and treatment. Bipolar Disord 2:27–36CrossRefPubMedGoogle Scholar
  31. Rainbow TC, Parsons B, Wolfe BB (1984) Quantitative autoradiography of β1- and β2-adrenergic receptors in rat cerebellum and cerebral cortex. Proc Natl Acad Sci U S A 81:1585–1589PubMedCrossRefGoogle Scholar
  32. Rothwell NJ, Stock MJ, Sudera DK (1987) Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the beta2-adrenoceptor agonist clenbuterol. Br J Pharmacol 90:601–607PubMedGoogle Scholar
  33. Tallarida RJ (2002) The interaction index: a measure of drug synergism. Pain 98:163–168CrossRefPubMedGoogle Scholar
  34. Tanaka KF, Kashima H, Suzuki H, Ono K, Sawada M (2002) Existence of functional beta1- and beta2-adrenergic receptors on microglia. J Neurosci Res 70:232–237CrossRefPubMedGoogle Scholar
  35. Teixeira MM, Rossi AG, Giembycz MA, Hellewell PG (1996) Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation. Br J Pharmacol 11:2099–2106Google Scholar
  36. Van Lambalgen AA, van Kraats AA, Mulder MF, van den Bos GC, Teerlink T, Thijs LG (1993) Organ blood flow and distribution of cardiac output in dopexamine- or dobutamine-treated endotoxemic rats. J Crit Care 8:117–127CrossRefPubMedGoogle Scholar
  37. Wei ZY, Karim F, Roerig SC (1996) Spinal morphine/clonidine antinociceptive synergism: involvement of G proteins and N-type voltage-dependent calcium channels. J Pharmacol Exp Ther 278:1392–1407PubMedGoogle Scholar
  38. Yamashita N, Yamauchi M, Baba J, Sawa A (1997) Phosphodiesterase type 4 that regulates cAMP level in cortical neurons shows high sensitivity to rolipram. Eur J Pharmacol 337:95–102CrossRefPubMedGoogle Scholar
  39. Ye Y, O'Donnell JM (1996) Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase in rat cerebral cortex. J Neurochem 66:1894–1902PubMedCrossRefGoogle Scholar
  40. Ye Y, Conti M, Houslay MD, Farooqui SM, Chen M, O'Donnell JM (1997) Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem 69:2397–2404PubMedCrossRefGoogle Scholar
  41. Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, Kobayashi J, Yamazaki F, Tanaka H, Nagai H (1997) Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Gen Pharmacol 29:633–638CrossRefPubMedGoogle Scholar
  42. Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'Donnell JM (2000) Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 23:198–204CrossRefPubMedGoogle Scholar
  43. Zhang HT, Frith SA, Wilkins J, O'Donnell JM (2001) Comparison of the effects of isoproterenol administered into the hippocampus, frontal cortex, or amygdala on behavior of rats maintained by differential reinforcement of low response rate. Psychopharmacology (Berl) 159:89–97CrossRefGoogle Scholar
  44. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O'Donnell JM (2002) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27:587–595PubMedGoogle Scholar
  45. Zhang HT, Huang Y, O'Donnell JM (2003) Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats. Psychopharmacology (Berl) 170:102–107CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Han-Ting Zhang
    • 1
    Email author
  • Ying Huang
    • 1
  • Kathleen Mishler
    • 1
  • Sandra C. Roerig
    • 2
  • James M. O'Donnell
    • 1
  1. 1.Department of PharmacologyThe University of Tennessee Health Science CenterMemphisUSA
  2. 2.Department of Pharmacology and TherapeuticsLouisiana State University Health Sciences CenterShreveportUSA

Personalised recommendations